ImmuPharma plc (LON:IMM – Get Free Report) shares were up 8% during trading on Thursday. The stock traded as high as GBX 4.30 and last traded at GBX 3.97. 1,687,495 shares changed hands during trading, a decline of 31% from the average session volume of 2,456,595 shares. The stock had previously closed at GBX 3.67.
ImmuPharma Stock Performance
The business has a 50-day simple moving average of GBX 3.64 and a two-hundred day simple moving average of GBX 4.78. The company has a market capitalization of £27.95 million, a price-to-earnings ratio of -5.39 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last posted its quarterly earnings data on Tuesday, September 15th. The company reported GBX (0.84) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 559.87%. Research analysts predict that ImmuPharma plc will post -339.00 EPS for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
- Constellation Energy’s Nuclear Expansion Gets a $5 Billion Opening, Not a Guarantee
- Plugging In: Vertiv Cashes In On AI Demand
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
